Tone mix
Week by week 51 weeks
Share of Immunome, Inc.'s 127 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Nov 24, 2025 · tone +100Immunome (NASDAQ:IMNM) Upgraded at Wall Street Zen+91
- Week of Sep 7, 2026 · tone +100HC Wainwright Reiterates Buy Rating for Immunome (NASDAQ:IMNM)+87
- Week of Sep 28, 2026 · tone +100Immunome's IM-1340 Receives FDA IND Clearance For Advanced Solid Tumors+83
- Week of May 25, 2026 · tone +100Immunome (NASDAQ:IMNM) Rating Increased to Strong-Buy at Barclays+70
- Week of Oct 19, 2026 · tone 0Recent Investment Analysts' Ratings Updates for Immunome (IMNM)-62
- Week of Jul 13, 2026 · tone +98What This Immunome Sale Means a Day Before a Big FDA Milestone+60
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Immunome, Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 1 | 0 |
| Last 30 sessions | 6 | +49 |
| Last 90 sessions | 30 | +26 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 22, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletRecent Investment Analysts' Ratings Updates for Immunome (IMNM)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Recent Investment Analysts' Ratings Updates for Immunome (IMNM) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 16, 2026
1 headline, average tone +96: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 2 outletsImmunome's Varegacestat: Could It Become The Second FDA-Approved Desmoid Tumor Treatment?Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Immunome's Varegacestat: Could It Become The Second FDA-Approved Desmoid Tumor Treatment? | www.rttnews.com | 2 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
2 headlines, average tone +50: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.dailypolitical.com · 1 outletImmunome, Inc. (NASDAQ:IMNM) Stock Rated "Moderate Buy" by Sell-Side BrokeragesPositive
- www.themarketsdaily.com · 1 outletArbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial ComparisonNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Immunome, Inc. (NASDAQ:IMNM) Stock Rated "Moderate Buy" by Sell-Side Brokerages | www.dailypolitical.com | 1 | Positive |
| Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial Comparison | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 1, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletImmunome's IM-1340 Receives FDA IND Clearance For Advanced Solid TumorsPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Immunome's IM-1340 Receives FDA IND Clearance For Advanced Solid Tumors | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, September 22, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletUltragenyx Pharmaceutical (NASDAQ:RARE) and Immunome (NASDAQ:IMNM) Head-To-Head ContrastNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ultragenyx Pharmaceutical (NASDAQ:RARE) and Immunome (NASDAQ:IMNM) Head-To-Head Contrast | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Immunome, Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.